Clinical predictors of overall survival in patients with diffuse large B-cell lymphoma
| Clinical features . | All patients, n (%)(n = 292) . | WT-TP53, n (%)(n = 190) . | Mutated TP53, n (%)(n = 102) . | P* . | Hazard ratio . | 95% CI . | P† . |
|---|---|---|---|---|---|---|---|
| Sex | |||||||
| Male | 125 (51) | 90 (49) | 35 (55) | 0.471 | 1.3 | 0.7-2.4 | 0.404 |
| Female | 121 (49) | 92 (51) | 29 (45) | ||||
| Age at diagnosis | |||||||
| Younger than 60 y | 115 (46) | 76 (40) | 39 (62) | 0.003 | 0.5 | 0.3-0.9 | 0.022 |
| At least 60 y | 137 (54) | 113 (60) | 24 (38) | ||||
| Stage | |||||||
| I/II | 115 (46) | 82 (43) | 33 (52) | 0.214 | 0.8 | 0.4-1.4 | 0.390 |
| III/IV | 137 (54) | 107 (57) | 30 (48) | ||||
| B symptoms | |||||||
| No | 138 (60) | 109 (59) | 29 (63) | 0.610 | 0.7 | 0.3-1.4 | 0.279 |
| Yes | 93 (40) | 76 (41) | 17 (37) | ||||
| No. of extranodal sites | |||||||
| Fewer than 2 | 211 (84) | 160 (85) | 51 (84) | 0.844 | 0.8 | 0.3-1.7 | 0.490 |
| At least 2 | 39 (16) | 29 (15) | 10 (16) | ||||
| Serum LDH level | |||||||
| Normal | 90 (40) | 78 (47) | 12 (20) | < 0.001 | 0.3 | 0.1-0.8 | 0.017 |
| Elevated | 135 (60) | 88 (53) | 47 (80) | ||||
| Performance score | |||||||
| Low | 72 (31) | 58 (31) | 14 (31) | 0.990 | 1.0 | 0.5-2.1 | 0.969 |
| High | 160 (69) | 129 (69) | 31 (69) | ||||
| Size of largest tumor | |||||||
| Less than 10 cm | 146 (76) | 110 (81) | 36 (64) | 0.014 | 0.8 | 0.4-1.5 | 0.418 |
| At least 10 cm | 46 (24) | 26 (19) | 20 (36) | ||||
| IPI risk group | |||||||
| Low (0-2) | 155 (66) | 110 (63) | 45 (78) | 0.035 | 0.6 | 0.3-1.1 | 0.105 |
| High (3-5) | 79 (34) | 66 (38) | 13 (22) | ||||
| Initial chemotherapy | |||||||
| CHOP/CHOP-like | 234 (89) | 161 (88) | 73 (91) | 0.436 | 1.0 | 0.4-2.4 | 0.971 |
| Other | 29 (11) | 22 (12) | 7 (9) | ||||
| Initial radiation therapy | |||||||
| None | 195 (74) | 126 (69) | 69 (86) | 0.004 | 1.1 | 0.5-2.5 | 0.748 |
| Involved/extended field | 67 (26) | 56 (31) | 11 (14) | ||||
| Treatment response | |||||||
| Complete remission | 157 (66) | 123 (69) | 34 (57) | 0.089 | 0.2 | 0.1-0.4 | < 0.001 |
| Partial response | 37 (15) | 27 (15) | 10 (17) | ||||
| No response | 14 (6) | 8 (4) | 6 (10) | ||||
| Progressive disease | 31 (13) | 21 (12) | 10 (17) | ||||
| Clinical features . | All patients, n (%)(n = 292) . | WT-TP53, n (%)(n = 190) . | Mutated TP53, n (%)(n = 102) . | P* . | Hazard ratio . | 95% CI . | P† . |
|---|---|---|---|---|---|---|---|
| Sex | |||||||
| Male | 125 (51) | 90 (49) | 35 (55) | 0.471 | 1.3 | 0.7-2.4 | 0.404 |
| Female | 121 (49) | 92 (51) | 29 (45) | ||||
| Age at diagnosis | |||||||
| Younger than 60 y | 115 (46) | 76 (40) | 39 (62) | 0.003 | 0.5 | 0.3-0.9 | 0.022 |
| At least 60 y | 137 (54) | 113 (60) | 24 (38) | ||||
| Stage | |||||||
| I/II | 115 (46) | 82 (43) | 33 (52) | 0.214 | 0.8 | 0.4-1.4 | 0.390 |
| III/IV | 137 (54) | 107 (57) | 30 (48) | ||||
| B symptoms | |||||||
| No | 138 (60) | 109 (59) | 29 (63) | 0.610 | 0.7 | 0.3-1.4 | 0.279 |
| Yes | 93 (40) | 76 (41) | 17 (37) | ||||
| No. of extranodal sites | |||||||
| Fewer than 2 | 211 (84) | 160 (85) | 51 (84) | 0.844 | 0.8 | 0.3-1.7 | 0.490 |
| At least 2 | 39 (16) | 29 (15) | 10 (16) | ||||
| Serum LDH level | |||||||
| Normal | 90 (40) | 78 (47) | 12 (20) | < 0.001 | 0.3 | 0.1-0.8 | 0.017 |
| Elevated | 135 (60) | 88 (53) | 47 (80) | ||||
| Performance score | |||||||
| Low | 72 (31) | 58 (31) | 14 (31) | 0.990 | 1.0 | 0.5-2.1 | 0.969 |
| High | 160 (69) | 129 (69) | 31 (69) | ||||
| Size of largest tumor | |||||||
| Less than 10 cm | 146 (76) | 110 (81) | 36 (64) | 0.014 | 0.8 | 0.4-1.5 | 0.418 |
| At least 10 cm | 46 (24) | 26 (19) | 20 (36) | ||||
| IPI risk group | |||||||
| Low (0-2) | 155 (66) | 110 (63) | 45 (78) | 0.035 | 0.6 | 0.3-1.1 | 0.105 |
| High (3-5) | 79 (34) | 66 (38) | 13 (22) | ||||
| Initial chemotherapy | |||||||
| CHOP/CHOP-like | 234 (89) | 161 (88) | 73 (91) | 0.436 | 1.0 | 0.4-2.4 | 0.971 |
| Other | 29 (11) | 22 (12) | 7 (9) | ||||
| Initial radiation therapy | |||||||
| None | 195 (74) | 126 (69) | 69 (86) | 0.004 | 1.1 | 0.5-2.5 | 0.748 |
| Involved/extended field | 67 (26) | 56 (31) | 11 (14) | ||||
| Treatment response | |||||||
| Complete remission | 157 (66) | 123 (69) | 34 (57) | 0.089 | 0.2 | 0.1-0.4 | < 0.001 |
| Partial response | 37 (15) | 27 (15) | 10 (17) | ||||
| No response | 14 (6) | 8 (4) | 6 (10) | ||||
| Progressive disease | 31 (13) | 21 (12) | 10 (17) | ||||